Nevertheless, it is not known whether deregulation of ABCC3, CPS1 and TRIP6 occurs in different types of paclitaxel-resistant ovarian carcinoma cells or how the deregulation is affected by the action of paclitaxel and novel taxane derivatives. Here, TRIP6 is linked to ovarian carcinoma.